Role of Pegylated Liposomal Doxorubicin (PLD) in Epithelial Ovarian Cancer

References

• Greenlee RT, Murray T, Bolden S, et al. Cancer statis-tics, 2000. CA Cancer J Clin 2000; 50: 7–33.
   PubMed Web of Science ®Google Scholar
• Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Rubin SC, Thomas G, et al. Epithelial ovari-an cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynaecologic Oncology, Philadelphia, PA, Lippincott-Raven, 1997; 1514-39.
   Google Scholar
• Kavanagh J, Tresukolos D, Edwards C, et al. Carboplatin reintroduction after taxane in patients with plat-inum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584–88.
   PubMed Web of Science ®Google Scholar
• Bookman M, Malmstrom H, Bolls G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345–52.
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405–10.
   PubMed Web of Science ®Google Scholar
• Shapiro JD, Millaward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89–93.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Harper PG, Buyse M. The role of anthracyclines in epithelial ovarian cancer. Ann Oncol 1999; 10 (Supp 1): S43-50.
   Google Scholar
• A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726–32.
   PubMed Web of Science ®Google Scholar
• Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9: 1668–74.
   Google Scholar
• Cordon AN, Granai CO, Rose P, et al. Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093–100.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catne R, Uziely B, et al. Prolongation of the circulation tissue and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes. Cancer Res 1994; 54: 987–992.
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R, et al. Liposomal doxoru-bicin: antitumor activity and unique toxicities during two com-plementary phase I studies. J Clin Oncol 1995; 13: 1777–85.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Martin F. Polyethylene glycol-coated (pegy-lated) liposomal doxorubicin: rationale for use for solid tumors. Drugs 1997; 54 (suppl 4): 15-21.
   Google Scholar
• Johnston SR, Gore ME. Caelyx: phase II studies in ovarian cancer. Eur J Cancer 2001; 37 (9): S8–S14.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93.
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, et al. Phase II trial of liposomal doxorubicin (40 mg/m2) in platinum /pacli-taxel- refractory ovarian and fallopian tube cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78: 369–72.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312–3322.
   Google Scholar
• Hansen SW, Tuxen MK, Sessa C et al. Gemcitabine in the treatment of ovarian cancer. Ann Oncol 1999; 10(S1): 51–53.
   Google Scholar
• Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002; 29(S1): 9–10.
   PubMed Web of Science ®Google Scholar
• ZOli W, Ricotti L, Barzanti F, et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80: 413–416.
   PubMed Web of Science ®Google Scholar
• Chow KU, Ries J, Weidmann E, et al. Induction of apoptosis using 2,2difluorodeoxycytidine (gemcitabine) in com-bination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 2000; 79: 485–492.
   Google Scholar
• D'Agostino G, Ferrandina G, Garganese G, et al. Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 2002; 62: 110–114.
   PubMed Web of Science ®Google Scholar
• Mathe G, Reizenstein P. Ethics and errors of clinical trials and the role and place of trial. Drugs Exp Clin Res: 1986; 12(1-3): 1–9.
   Google Scholar
• D'Agostino G, Ferrandina G, Ludovisi M et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer 2003; 89: 1180–84.
   Google Scholar
• Lorusso D, Naldini A, Testa A et al. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients: may a new treatment schedule improve toxicity profile? Oncology, 2004; in press.
   Google Scholar
• Hansen SW. Gemcitabine, platinum and Paclitaxel regi-mens in patients with advanced ovarian carcinoma. Sem Oncol 2002; 29 (Suppl I): 17-19.
   Google Scholar
• Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynaecological cancer. Gynecol Oncol 2000; 78: 143–7.
   PubMed Web of Science ®Google Scholar